The efficacy and duration of treatment with propranolol in children with cyclic vomiting syndrome in southern Iran

Haghighat, Mahmood; Memari, Hajar; Honar, Naser; Dehghani, Seyed Mohsen; Imanieh, Mohammad Hadi; Injoo, Seyed-Javad; Javaherizadeh, Hazhir

doi:10.5114/pg.2017.72105

Cited by 6 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Timely diagnosis and treatment with propranolol have been suggested in several studies. [15][16][17] All of the 504 children had emesis and vomiting, which consistent with other studies in the field, is characteristic of the disease. 18,19 The results indicated that the average incidence age was 52 months (4.3 years) and the average age at diagnosis was 69.9 months (5.8 years).…”

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Relapse Rate of Clinical Symptoms After Stopping Treatment in Children with Cyclic Vomiting Syndrome

Haghighat

Shahrebabak

Dehghani

et al. 2023

Middle East J Dig Dis

Self Cite

View full text Add to dashboard Cite

Background: Cyclic vomiting syndrome (CVS) is a chronic functional gastrointestinal disorder. It is characterized by recurrent episodes of vomiting typically separated by periods of symptom-free or baseline health. The present study aimed at evaluating the effectiveness of propranolol and the relapse rate of clinical symptoms after stopping treatment in children suffering from CVS. Methods: Records of 504 patients below the age of 18 years with CVS who were treated with propranolol from March 2008 to March 2018 were reviewed. The duration of follow-up was 10 years.Results: The average age of CVS affliction was 4.3 years and the average age at the diagnosis was 5.8 years. All subjects were treated with propranolol (for an average of 10 months). 92% of treated subjects were cured, causing a dramatic decrease in the rate of vomiting (P < 0.001). Only an average of 10.5% of the studied subjects (53 people) showed a relapse of symptoms after stopping the treatment. The results of a 10-year follow-up period of the patients showed that 24 had abdominal migraine and 6 had migraine headaches, all of whom lacked the symptoms of disease relapse (prognostic evaluation). Conclusion: The findings of this investigation show that the duration of treating CVS with propranolol could be shortened to 10 months with a low percent of symptoms relapse and this shortening may be effective in preventing the undesirable side effects of the drug. The presence of abdominal migraine and migraine headaches in patients after treatment accomplishment and the lack of disease relapse can be prognostic measures for this disease, which require intensive attention.

show abstract

Section: Discussionsupporting

confidence: 85%

“…15,16 Meanwhile, efficiency rate, lack of disease symptoms relapse after stopping treatment, and treatment duration (especially in children) are among important and unclear problems in previous reports and studies, which are the focus of the present study. Duration of the treatment period in children with CVS can also http://mejdd.org be useful in…”

mentioning

confidence: 97%

Relapse Rate of Clinical Symptoms After Stopping Treatment in Children with Cyclic Vomiting Syndrome

Haghighat

Shahrebabak

Dehghani

et al. 2023

Middle East J Dig Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…As a result, not only their quality of life is not improved but also by discontinuation of prophylaxis, the risk of the transforming the episodic migraine to the chronic type increases, and subsequently, other major complications such as cardiovascular incidents increase. [14] The objective of this research was to evaluate the use of VFL as an alternative to the combination of nortriptyline and propranolol, assuming that it has fewer side effects with similar or greater effects on the frequency or severity of headaches, and thus, it is more tolerable in the long term.…”

Section: Discussionmentioning

confidence: 99%

Untitled

Mosarrezaii¹

2018

AJP

View full text Add to dashboard Cite

Background: Migraine is a debilitating neurological condition, which can be categorized into episodic and chronic groups based on its clinical pattern. Avoiding the risk factors exacerbating migraine is not enough to reduce the frequency and severity of migraine headaches, and in the case of non-receiving proper drug treatment, episodic migraines have the potential to become chronic, which increases the risk of cardiovascular complications and leaves great impact on the quality of life of patients and increasing the health-care costs. The objective of this research was to compare the effects of venlafaxine (VFL) and nortriptyline and propranolol in preventing migraines. Methods: This research is an interventional study performed on 60 patients with migraine admitted to the neurological clinic. Patients were visited at 3 time intervals. In each stage, the variables of headache frequency, headache severity, nausea, vomiting, and drowsiness were recorded. Data were analyzed using SPSS 23 software. Results: VFL drug with a daily dose of 37.5 mg is not only more tolerable in the long term but also leaves better effect in reducing the frequency and severity of headaches compared to the combination of nortriptyline and propranolol. Conclusion: VFL is an appropriate, effective, and tolerable alternative to migraine treatment.

show abstract

“…Its efficacy was evaluated in 311 patients across 2 extensive prospective studies and 1 retrospective study. 22,26,27 Haghighat et al compared the effectiveness of propranolol with that of amitriptyline, and observed that 89% of patients treated with propranolol demonstrated a "good response" without side effects, in contrast to a 56% overall response rate in patients treated with amitriptyline. 22 Furthermore, no side effects were reported among the propranolol-treated patients, unlike the amitriptyline group.…”

Section: Treatment Of Cvs Comparing Standard Therapy Withmentioning

confidence: 99%

Treatment Options for Cyclic Vomiting Syndrome: A Real‐World, Single‐Center Experience with Systematic Literature Review and Meta‐Analysis

Falsaperla,

Scalia,

Collotta

et al. 2023

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The optimal therapeutic management of cyclic vomiting syndrome (CVS) remains elusive. The objective of this study is to document our clinical experience in the Pediatric Department of San Marco Hospital and to survey the literature on pediatric CVS treatment, aiming to update information on the most effective treatment strategies for this not‐so‐uncommon condition.Data from 70 patients with CVS, admitted to our Pediatric Department between September 2011 and December 2021, were aggregated and included in the study. A systematic review of the literature was conducted in accordance with the PRISMA guidelines. The quality of the included studies was assessed using the QUADAS‐2 tool and the AMSTAR‐2 method.Treatment responses, as observed both in the literature and in our own experience, are variable. In our cohort, Topiramate demonstrated superiority over other pharmacological treatments, exhibiting an efficacy of 85% in the treated patients.A universally accepted treatment protocol for pediatric CVS has yet to be established. The efficacy of first‐line treatments is generally suboptimal, suggesting that Topiramate might serve as a safe and effective primary therapeutic option for pediatric CVS.This article is protected by copyright. All rights reserved

show abstract

The efficacy and duration of treatment with propranolol in children with cyclic vomiting syndrome in southern Iran

Cited by 6 publications

References 20 publications

Relapse Rate of Clinical Symptoms After Stopping Treatment in Children with Cyclic Vomiting Syndrome

Relapse Rate of Clinical Symptoms After Stopping Treatment in Children with Cyclic Vomiting Syndrome

Untitled

Treatment Options for Cyclic Vomiting Syndrome: A Real‐World, Single‐Center Experience with Systematic Literature Review and Meta‐Analysis

Contact Info

Product

Resources

About